Skip to Footer content CONTACT US About Us The Science Pipeline Investor Relations News & Events Careers A future free from neuro­degenerative disease Yumanity Therapeutics is a clinical-stage biopharmaceutical company that is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Learn More Yumanity is Accelerating the Revolution in the Treatment of Neuro­degenerative Diseases Rapidly Advancing Clinical-Stage Pipeline Lead program for Parkinson’s (PD) in Phase 1 and plans to advance program to Phase 2 Potentially first-in-class disease-modifying mechanism of action Transformative Scientific Foundation & Prolific Drug Discovery Platform Technology originally licensed from Whitehead Institute uncovered 15+ novel CNS targets Rapidly screen for disease-modifying drugs to overcome toxicity of misfolded proteins in disease-causing gene networks Applying Rare Diseases and Oncology R&D Principles to Neurology Leveraging biomarkers to guide development and selecting well-defined patient populations Management team with deep experience in neurology, rare disease and oncology drug development Yumanity News, Events & Press Yumanity’s drug discovery platform allows the Company to rapidly screen for disease-modifying therapies for Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD) and Alzheimer’s Disease (AD). Press Release November 10, 2021 Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2 News November 10, 2021 Yumanity Therapeutics plans to advance program to Phase 2 Event September 9, 2021 Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference Press Release August 16, 2021 Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants About Us Pipeline The Science Investor Relations News & Events Careers Contact Us Terms of Use Yumanity Therapeutics announces Positive Top-Line Results of Phase 1b Trial Read More